Comparison of the alteration of the concentration of C-peptide in 24-h urine according to the combination patterns of hypoglycemic agents in type 2 diabetes patients

Diabetes Research and Clinical Practice

Volumn 77, Issue 3 SUPPL., 2007, Pages

  Jung, Chan Hee ^a   Rhee, Eun Jung ^a   Kim, Eun Ran ^a   Kim, Se Yeon ^a   Shin, Hun Sub ^b   Lee, Won Young ^a   Oh, Ki Won ^a   Park, Sung Woo ^a   Kim, Sun Woo ^a  

^a School of Medicine   (South Korea)

^b Armed Forces Capital Hospital   (South Korea)

Author keywords

Insulin sensitizer; Pancreatic beta cell; Type 2 diabetes mellitus; Urinary C peptide

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; COMBINATION CHEMOTHERAPY; DIABETES CONTROL; DIABETES MELLITUS; DISEASE DURATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RADIOIMMUNOASSAY; TREATMENT OUTCOME; URINARY EXCRETION; URINE LEVEL;

AGED; BLOOD GLUCOSE; C-PEPTIDE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED;

EID: 34547768051     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.01.059     Document Type: Article

References (22)

1. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 287 (2002) 360-372
2. Turner R.C., Cull C.A., Frighi V., and Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J. Am. Med. Assoc. 281 (1999) 2005-2012
3. Matthews D.R. Insulin resistance and β-cell function-a clinical perspective. Diabetes Obestet. Metab. 3 (2001) S28-S33
4. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44 (1995) 1249-1258
5. Tyrberg B., and Levine F. Current and future treatment strategies for type 2 diabetes: the beta-cell as a therapeutic target. Curr. Opin. Invest. Drugs 2 (2001) 1568-1574
6. Riddle M.D. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol. Metab. Clin. North Am. 34 (2005) 77-98
7. Hoekstra J.B.L., Van Rijn H.J.M., Erkelens D.W., and Thijssen J.H.H. C-peptide. Diabetes Care 5 (1982) 438-446
8. Meistas M., Zadik Z., Margolis S., and Kowarski A. Correlation of urinary excretion of C-peptide with the integrated concentration and secretion rate of insulin. Diabetes 30 (1981) 639-643
9. Meistas M., Rendell M., Margolis S., and Kowarski A. Estimation of the secretion rate of insulin from the urinary excretion rate of C-peptide. Study in obese and diabetic subjects. Diabetes 31 (1982) 449-453
10. Brodows R.G. Use of urinary C-peptide to estimate insulin secretion during starvation. J. Clin. Endocrinol. Metab. 61 (1985) 654-657
11. Hoogwerf B., and Goetz F.C. Urinary C-peptide: a simple measure of integrated insulin production with emphasis on the effects of body size, diet and corticosteroids. J. Clin. Endocrinol. Metab. 56 (1988) 60-67
12. Pasquali R., Buratti P., Casimirri F., Patrono D., Capelli M., Melchionda N., et al. Urinary excretion rate of C-peptide in fed and fasted obese humans. Acta Endocrinol. 118 (1988) 38-44
13. Lindstrom T., Arnqvist H.J., Ludvigsson J., and Schenck H. C-peptide profiles in patients with non-insulin-dependent diabetes mellitus before and during insulin treatment. Acta Endocrinol. 126 (1992) 477-483
14. Aoki Y. Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide. Diabetes Res. Clin. Pract. 9 (1991) 165-174
15. Ovalle F., and Bell D.S. Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obestet. Metab. 4 (2002) 56-59
16. Bell D.S. β-Cell rejuvenation with thiazolidinediones. Am. J. Med. 115 (2003) 20S-23S
17. Kerenyi Z., Samer H., James R., Yan Y., and Stewart M. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 63 (2004) 213-223
18. Wolffenbuttel B.H., Gomis R., Squatrito S., Jones N.P., and Patwardhan R.N. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabetes Med. 17 (2000) 40-47
19. Lupi R., Del Guerra S., Marselli L., Bugliani M., Boggi U., and Mosca F. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion. Am. J. Physiol. Endocrinol. Metab. 286 (2004) E560-E567
20. Arner P. Free fatty acids-do they play a central role in type 2 diabetes?. Diabetes Obestet. Metab. 3 (2001) S11-S19
21. 2 and aminoguanidine. A role for peroxisome proliferators-activated receptor γ activation and iaNOS expression. J. Biol. Chem. 274 (1999) 18702-18708
22. Leiter L.A. β-Cell preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes. Diabetes Med. 22 (2005) 963-972